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Abstract: The anticonvulsant hypersensitivity syndrome, also
known as drug rash eosinophilia and systemic symptoms (DRESS),
is a rare but severe form of adverse cutaneous reaction. Several
aromatic anticonvulsant drugs, such as carbamazepine (CBZ), phe-
nytoin, or phenobarbital have been frequently associated with the
onset of DRESS. Cross-reactivity among the aromatic anticonvul-
sants frequently occurs (40 to 80% of patients). However, cross
reactivity with other drugs such as betalactams have exceptionally
been reported. We report a clinical observation describing a DRESS
associated with CBZ with a subsequent hypersensitivity to amoxi-
cillin (AMX). A 34-year-old male with a 20-year history of epilepsy
was treated with valproic acid and phenobarbital. As he had frequent
convulsive fits, CBZ was added. Thirty-four days later, the patient
developed hyperthermia (39.5°C), cervical lymphadenopathy, and
generalized cutaneous exfoliated maculae and papulae. Biochemical
investigation was characterized by a white cell count of (16.1 
103/L, 17% eosinophils) and increased levels of aspartate amino-
transferase and alanine aminotransferase (50 and 116 IU/L, respec-
tively). CBZ was discontinued. One month later, all the symptoms
were progressively relieved. Six weeks after complete recovery,
prick and patch skin tests were performed. They were strongly
positive at 48-hour reading. About 2 years later, the patient exhibited
an extensive pruritic skin rash, 2 days after AMX intake. Laboratory
exams showed eosinophilia (7%) but neither elevated liver enzymes
nor renal dysfunction. All these symptoms have disappeared 5 days
after AMX withdrawal. Intradermal test to AMX was positive but
not to other betalactams. Throughout this clinical observation, we
report a CBZ-induced DRESS and describe the possibility of cross
reactivity between CBZ and AMX. This cross reactivity was ob-
served despite the lack of chemical similarity between both drugs.
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Drug reaction with eosinophilia and systemic symptoms(DRESS) also known as hypersensitivity syndrome, is
rare but one of the most severe forms of drug reaction. It
associates fever, skin eruption, eosinophilia, and multiple
organ involvement (lymph node enlargement, hepatitis, pneu-
monitis, renal dysfunction, and so forth).1
Aromatic anticonvulsant drugs [eg, phenytoin, pheno-
barbital, and carbamazepine (CBZ)] are still the principal
drugs that elicit this syndrome. The latter has been attributed
to a disorder in the metabolic patterns of the aromatic anti-
convulsants leading to an excess of toxic metabolite.2 Cross
reactivity explained by a chemical or antigenic similitude has
been well described between anticonvulsant drugs.3,4 How-
ever, limited data have reported the development of drug
hypersensitivity after a history of DRESS syndrome induced
by other chemically unrelated drugs.5,6 We report a case of
amoxicillin (AMX) hypersensitivity after DRESS syndrome
because of CBZ.
CASE REPORT
A 34-year-old male with a 20-year history of epilepsy
was treated with valproic acid (500 mg 3 times daily) and
phenobarbital (200 mg once a day). As he had frequent
convulsive fits, CBZ was added. Thirty-four days later, the
patient developed hyperthermia and cervical lymphadenopa-
thy. Initially, he was diagnosed with lymphadenitis and, thus,
a therapy for AMX-clavulanic acid (1 g twice a day) and
acetaminophen (500 mg 3 times a day), was started. Two
days later, a generalized cutaneous eruption (exfoliated and
confluent maculae and papulae associated with facial angio-
edema) was also observed. The laboratory findings showed
an abnormal white cell count (16.1  103/l, 17% eosino-
phils), a liver dysfunction with an aspartate aminotransferase
(AST) level of 50 IU/L and an alanine AST level (ALT) of
116 IU/L (normal 4–40 IU/L), a lactate deshydrogenase level
of 3197 (normal 190–430 IU/L). The platelet count, INR, the
serum levels of immunoglobulins, and the renal function
were conversely normal and no atypical lymphocytes were
found. The thoracic imaging did not show any abnormalities.
The serologic test of Human Herpes Virus 6 (HHV6) was
positive (IgM anti-HHV6 detected). Tests for other viral infec-
tions including cytomegalovirus, Epstein-Barr virus, hepatitis B
and C, and HIV were all negative. CBZ, AMX-clavulanic acid,
and acetaminophen were then discontinued and cetirizine (10
mg once a day) was administered. About 1 month later, the skin
eruption, fever, lymphadenopathy, liver dysfunction, and eosin-
ophilia progressively disappeared. Six weeks after complete
recovery, a patch test to CBZ was performed and was strongly
positive at 48-hour reading (Fig. 1).
About 2 years later, the patient was treated with AMX
(2 g daily) for a dental abutment. On day 2 of this treatment,
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he presented a generalized maculo-papular eruption with
neither fever nor lymph node swelling. The laboratory find-
ings showed eosinophilia (white cell count: 8.1 103/l, 7%
eosinophils) with normal hepatic and renal function. AMX
was discontinued with favorable course 1 week later. Two
months later, an intradermal test to AMX (20 mg/ml) was
performed, and was positive at 48-hour reading (Fig. 2). An
intradermal test to penicillin G (20 000 IU/ml), cefazolin (20
mg/ml), and cefotaxime (20 mg/ml) was conversely negative
(Fig. 2).
DISCUSSION
We describe a case of hypersensitivity to AMX after a
DRESS induced by CBZ. We believe that DRESS would
obviously be related to CBZ in view of the after arguments:
1) a clear temporal relationship between the administration of
CBZ and the symptoms onset (5 and 10 weeks, respectively,
typically 1 to 12 weeks7,8); 2) remission of the symptomato-
logical pattern after withdrawal of this drug; 3) the associa-
tion of different symptoms evoking a clinical picture of
DRESS syndrome; and 4) a positive patch test to CBZ.
Regarding the subsequent episode of hypersensitivity in our
patient, the responsibility of AMX was established according
to the clear temporal relationship between AMX intake and
the reaction onset, the remission of the symptoms after AMX
withdrawal and the positive intradermal test to AMX.
DRESS is a nosological entity characterized mainly by a
potentially life-threatening drug-induced cutaneous eruption.
Several drugs including anticonvulsant agents, sulfonamides,
and allopurinol, have been associated with an increased risk of
inducing such a syndrome. The clinical picture of DRESS
includes fever, morbiliform eruption, lymphadenopathy, pleural
effusion, liver and renal dysfunctions, hematological abnormal-
ities such as eosinophilia, and atypical lymphocytosis.9 Our
patient did not exhibit any renal or respiratory disorders (creat-
inine and thoracic imaging were normal).
According to the results of some studies,10,11 it seems
that several mechanisms must simultaneously occur to pro-
duce the massive specific and nonspecific T cell activity that
is a characteristic feature of DRESS. Enough exposure time
to a drug able to form chemically active toxic metabolites is
required (or, alternatively, the native drug or its metabolites
must be exposed on MHCII-matched antigen presenting cells
to specific cytotoxic T cells). It has been suggested that a
defect in the epoxide hydroxylases, which induces the accu-
mulation of CBZ toxic metabolites, may lead to cell death or
contribute to the formation of antigens triggering the immune
reaction involved in DRESS.2 However, in our patient be-
cause the patch test was positive to CBZ, it can be argued that
the drug reaction may be caused by CBZ itself and not its
reactive metabolite. It is reported that a reactivation of a
latent HHV-6 infection during a period of transient immuno-
suppression would stimulate a massive expansion of HHV-
6–specific and –nonspecific bystander CD8 and CD4 T
cells and cause full development of DRESS symptoms. How-
ever, it is not completely clear whether HHV6 reactivation is
a consequence of a strong immune modulation during
DRESS or a cofactor that favors the manifestation of this
syndrome.12 Anyway, we did not notice a reactivation of
HHV6 in our patient because the serological test showed a
primary infection. As our patient exhibited a hypersensitivity
reaction to AMX after a DRESS episode, it can be argued that
a possible AMX-CBZ cosensitization has occurred. AMX
had been administered previously during the episode of
DRESS in our patient. We had a positive intradermal test to
AMX with 48 hours reading, denoting a delayed hypersensi-
tivity to this drug. The intradermal test to other betalactams
was negative, revealing a lack of cross reactivity between
AMX and these drugs. The hypersensitivity reaction that
FIGURE 1. Positive patch test to CBZ at 48-hour reading.
FIGURE 2. Positive intradermal test to AMX at 48-hour
reading.
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occurred in our patient was mild compared with the initial
one. Indeed, we noticed a skin rash and eosinophilia with no
organ involvement. Cross reactivity between anticonvulsant
drugs has been described widely in the literature when the
initial reaction is DRESS. It is known to be as high as 80%
among aromatic ones.4 We have recently described a cross
reactivity between CBZ and lamotrigine, aromatic and non-
aromatic anticonvulsants, respectively.13 To our knowledge,
5 clinical observations describing a sensitization to chemi-
cally different drugs taken during a previous episode of
anticonvulsant-induced DRESS have been reported so far.5,6
Only 2 cases reported a possible AMX-CBZ cosensitization.
The first described a generalized rash and facial angioedema
occurring 7 hours after taking AMX in a patient who took this
drug during a previous CBZ-related DRESS. The second
refers to a 68-year-old woman with a history of CBZ-induced
DRESS who had a positive patch test to AMX. In this respect,
some authors have suggested that the supposed cross-reac-
tions between such drugs, without any chemical or antigenic
similitude, are because of the fact that the drug responsible
for the second reaction was administered during the immu-
nologic depression occurring during a first DRESS episode.14
Our clinical observation appears to support this hypothesis. In
view of these considerations, it has been suggested that
DRESS episode may elicit a massive nonspecific activation
of the immune system, which will provide the enhanced
expression of costimulatory molecules and proinflammatory
cytokines. The latter will allow a more efficient presentation
of chemical antigens to antigen-presenting cells and conse-
quently decrease the level of tolerance to drugs,5 in particular
those known to be potentially immunogenic, such as AMX
antibiotics whether the drug was taken or not during the
initial phase of DRESS.
CONCLUSION
Throughout this report, we point out a possible cosen-
sitization to chemically or antigenically unrelated drugs, CBZ
on the one hand, and AMX, on the other hand. Thus, clini-
cians should be aware when prescribing AMX to a patient
with a previous history of DRESS syndrome. Skin tests to
betalactams should be performed in such a patient to identify
whether he could or not tolerate these drugs.
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